Tourette Syndrome

4
Pipeline Programs
5
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
1
1
pramipexole 0.125 mg BIDPhase 31 trial
pramipexole immediate releasePhase 21 trial
Active Trials
NCT00558467Completed63
NCT00681863Terminated45
Teva
TevaIsrael - Petach Tikva
2 programs
2
TEV-50717Phase 31 trial
TEV-50717Phase 31 trial
Active Trials
NCT03571256Completed158Est. Dec 2019
NCT03567291Terminated228Est. May 2020
Ipsen
IpsenChina - Tianjin
1 program
Abobotulinum toxin AN/A1 trial
Active Trials
NCT02187679Unknown30
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Active TreatmentN/A1 trial
Active Trials
NCT03642951WithdrawnEst. Jun 2022
Alliance Pharmaceuticals
1 program
Deep Brain StimulationN/A4 trials
Active Trials
NCT06388291Completed18Est. Jun 2025
NCT04811807Unknown50Est. Nov 2024
NCT01306539Completed20Est. Dec 2014
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaTEV-50717
TevaTEV-50717
Boehringer Ingelheimpramipexole 0.125 mg BID
Alliance PharmaceuticalsDeep Brain Stimulation
Boehringer Ingelheimpramipexole immediate release
Alliance PharmaceuticalsDeep Brain Stimulation
Alliance PharmaceuticalsDeep Brain Stimulation
City TherapeuticsActive Treatment
IpsenAbobotulinum toxin A
Alliance PharmaceuticalsDeep Brain Stimulation

Clinical Trials (10)

Total enrollment: 622 patients across 10 trials

NCT03571256TevaTEV-50717

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

Start: May 2018Est. completion: Dec 2019158 patients
Phase 3Completed
NCT03567291TevaTEV-50717

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Start: May 2018Est. completion: May 2020228 patients
Phase 3Terminated
NCT00681863Boehringer Ingelheimpramipexole 0.125 mg BID

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

Start: May 200845 patients
Phase 3Terminated
NCT00296920Alliance PharmaceuticalsDeep Brain Stimulation

Deep Brain Stimulation for Refractory Major Depression

Start: Jun 200210 patients
Phase 3Completed
NCT00558467Boehringer Ingelheimpramipexole immediate release

Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

Start: Jan 200863 patients
Phase 2Completed
NCT06388291Alliance PharmaceuticalsDeep Brain Stimulation

Deep Brain Stimulation in Tourette Syndrome

Start: Aug 2022Est. completion: Jun 202518 patients
N/ACompleted
NCT04811807Alliance PharmaceuticalsDeep Brain Stimulation

Clinical Response of Impulsivity After Brain Stimulation in Parkinson's Disease

Start: Oct 2021Est. completion: Nov 202450 patients
N/AUnknown
NCT03642951City TherapeuticsActive Treatment

Multi-site Transcranial Magnetic Stimulation Therapy of the Supplementary Motor Area in Children With Tourette Syndrome

Start: Jul 2019Est. completion: Jun 2022
N/AWithdrawn
NCT02187679IpsenAbobotulinum toxin A

Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome

Start: Jan 201430 patients
N/AUnknown
NCT01306539Alliance PharmaceuticalsDeep Brain Stimulation

Neuropsychiatric Effects of Deep Brain Stimulation in Patients With Parkinson's Disease

Start: Jul 2008Est. completion: Dec 201420 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space